PPD Clinical Research has renewed its collaboration with Medidata, in a move that maintains its access to the latter’s clinical trial technology.
The agreement – financial terms of which were not disclosed – is focused on PPD’s “TrueCast” technology, which is a system designed to shorten study timelines using patient recruitment and site performance data to deliver powerful predictive models and advanced analytics.
PPD’s system – which is built on an artificial intelligence system developed by Medidata - was launched in 2022.
The firm said, “the platform utilizes advanced artificial intelligence (AI) models to forecast cycle times and enrolment performance, enabling simplified scenario planning and optimized country and site selection.”
The extension also reflects Medidata’s longer running collaboration with PPD according to
Janet Butler, executive vice president and head of global sales, at the Dassault Systèmes-owned technology developer.
“Over the past 15 years, we have built a valued connection with the PPD clinical research business to enhance visibility and decision-making during clinical trials.
She added: “We look forward to working together to complete studies faster, boost drug development productivity, and ultimately bring life-changing treatments to patients sooner.”
PPD and Medidata have worked together since 2009. They claim to have collaborated on more than 1,000 clinical studies for biopharmaceutical and medical device companies across a broad range of therapeutic areas from oncology to vaccines.
Related news
News of the deal follows just a few weeks after Sanofi said it would continue to use Medidata technology in its production development programs.
At the time the French drug manufacturer said the collaboration will use an “eDiary” function within Medidata’s electronic clinical outcome assessment (eCOA) technology to create a library specific to vaccine studies.
“This library will accelerate future study set-up times, improve efficiency, and increase data quality, while ensuring patients have access to eDiaries that are easy to use,” Sanofi said.
Unsplash/RockStaar